MammaPrint helps you make the best-informed decisions

• gives a clear risk assessment for the recurrence of distant metastasis in your breast cancer patient
• adds a new quality of data to your prognostic tools
• gives detailed insight into the biology of your patient’s tumor
• assists you in developing tailor-made treatment plans

click to enlarge

Using data you can rely on

• independently validated in over 1,000 patients
• clinical utility proven in more than 12,000 tests
• the first and only diagnostic test of its kind cleared by the FDA
• fulfills global regulatory requirements - CE, ISO, CLIA, FDA

Download brochure